Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemsidomide + elranatamab
- Development stage
- Unknown
- Lead developer
- C4 Therapeutics, Inc.
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral, Subcutaneous
01
Overview
Cemsidomide plus elranatamab is an investigational combination regimen being developed for the treatment of relapsed/refractory multiple myeloma (RRMM). Cemsidomide (CFT7455) is an orally bioavailable small-molecule molecular glue degrader (MonoDAC degrader) that targets the transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos) via cereblon (CRBN) E3 ligase modulation, leading to direct anti-myeloma activity and T-cell activation. Elranatamab (ELREXFIO) is an FDA-approved bispecific T-cell engager (TCE) targeting B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, redirecting T-cell-mediated cytotoxicity against the tumor. The combination of cemsidomide and elranatamab, often administered alongside dexamethasone, is designed to synergistically enhance anti-myeloma efficacy by combining direct tumor cell degradation and robust T-cell activation with targeted T-cell redirection. The regimen is currently being evaluated in a Phase 1b clinical trial (NCT07280013 / CFT7455-1102) sponsored by C4 Therapeutics, with Pfizer supplying elranatamab.
- Other names
- CFT7455 + ElrexfioCFT7455 + elranatamabcemsidomide + Elrexfiocemsidomide + elranatamab + dexamethasonecemsidomide plus elranatamab
02
Targets
CD3E (T-cell surface glycoprotein CD3 epsilon chain receptor)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on cemsidomide + elranatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemsidomide + elranatamab.